
- Pharmaceutical Executive-03-01-2009
- Volume 0
- Issue 0
GSW Worldwide for MGI Pharma/Eisai's PONV
To educate anesthesiologists that post-operative nausea and vomiting (PONV) is "no fun for anyone," GSW Worldwide created WoozyWorld.com, a "non-amusement" that highlights the need for MGI Pharma's 72-hour antiemetic Aloxi.
WOOZYWORLD
GSW Worldwide
BRAND Market education for PONV CLIENT MGI Pharma/Eisai FROM LEFT: (Seated): Sean Cowan, creative director, digital wave; Kristan Early, vice president, creative director; (Standing): Dean Tepper, senior vice president, group creative director; Seth Quillin, senior vice president, digital operations
To educate anesthesiologists that post-operative nausea and vomiting (PONV) is "no fun for anyone," GSW Worldwide created
WoozyWorld includes information on the very real consequences of patients' post-operative side effects—with the goal to "make [anesthesiologists] care a little bit longer." "When patients undergo anesthesia, all anesthesiologists really care about is the first 24 hours after surgery," says Kristan Early, vice president, creative director. "Once patients are discharged, anesthesiologists feel their job is done. But in reality, a patient can still become sick once they arrive home or even days later."
Articles in this issue
over 16 years ago
Topin & Associates for Dusa's ClindaReachover 16 years ago
Saatchi & Saatchi for Sanofi-Aventis's Ambien CRover 16 years ago
Through the Looking Glassover 16 years ago
Wishbone for Barrier Thearpeutic's Vusionover 16 years ago
Fifth Annual Press Audit: Safety in the Spotlightover 16 years ago
Torre Lazur McCann for BMS & Sanofi Aventis's Plavixover 16 years ago
ICC for Sanofi Pasteur's TravelWise Programover 16 years ago
The New Sales Forceover 16 years ago
Flashpoint Medica for Indevus Pharmaceuticals's Supprelin LAover 16 years ago
TBWA\WorldHealth for Schering-Plough's NuvaRingNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.





